Highbridge Capital Management

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company's development pipeline includes several therapeutic candidates, such as BL-8040, a peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization. Another key candidate is AGI-134, an immuno-oncology agent aimed at solid tumors. Additionally, BioLineRx has developed BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company has established collaborations with prominent organizations, including MSD for cancer immunotherapy, MD Anderson Cancer Center to explore the combination of BL-8040 with KEYTRUDA in pancreatic cancer, and Genentech Inc. for studies involving BL-8040 and TECENTRIQ in solid tumors. Founded in 2003, BioLineRx is focused on addressing unmet medical needs and improving existing therapies in the pharmaceutical market.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Mithra Pharmaceuticals SA develops, manufactures, and markets innovative therapeutics focused on women's health, particularly in the areas of contraception, menopause, and hormone-dependent cancers. The company's key development candidates include Estelle, a fifth-generation oral contraceptive that has completed phase III clinical trials, and Donesta, a next-generation hormone therapy for menopausal symptoms currently in phase III trials. Additionally, Mithra is advancing several other products, such as Myring, a contraceptive vaginal ring, and Zoreline, a biodegradable implant for treating prostate and breast cancers. Established in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates in multiple regions, including Belgium, Europe, and beyond, and offers a comprehensive spectrum of services through its CDMO, catering to research, development, and specialist manufacturing needs.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

Invacare Corporation is a leading manufacturer and distributor of medical equipment focused on home health care and long-term care markets globally. Established in 1885 and headquartered in Elyria, Ohio, Invacare designs, manufactures, and distributes a wide range of products that assist individuals with mobility, respiratory needs, and essential daily activities. The company offers mobility solutions, including power and manual wheelchairs, as well as seating and positioning products. Its lifestyle offerings encompass pressure-relieving overlays, mattress systems, and personal care items. Additionally, Invacare provides respiratory therapy equipment, such as stationary and portable oxygen concentrators, alongside healthcare furnishings for long-term care settings. The company primarily sells its products through home medical equipment providers, residential care operators, and government health services, utilizing various distribution channels including retail and e-commerce. Invacare is committed to supporting individuals with diverse medical conditions, thereby promoting recovery and active lifestyles.

Invacare Corporation is a leading manufacturer and distributor of medical equipment focused on home health care and long-term care markets globally. Established in 1885 and headquartered in Elyria, Ohio, Invacare designs, manufactures, and distributes a wide range of products that assist individuals with mobility, respiratory needs, and essential daily activities. The company offers mobility solutions, including power and manual wheelchairs, as well as seating and positioning products. Its lifestyle offerings encompass pressure-relieving overlays, mattress systems, and personal care items. Additionally, Invacare provides respiratory therapy equipment, such as stationary and portable oxygen concentrators, alongside healthcare furnishings for long-term care settings. The company primarily sells its products through home medical equipment providers, residential care operators, and government health services, utilizing various distribution channels including retail and e-commerce. Invacare is committed to supporting individuals with diverse medical conditions, thereby promoting recovery and active lifestyles.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Mithra Pharmaceuticals SA develops, manufactures, and markets innovative therapeutics focused on women's health, particularly in the areas of contraception, menopause, and hormone-dependent cancers. The company's key development candidates include Estelle, a fifth-generation oral contraceptive that has completed phase III clinical trials, and Donesta, a next-generation hormone therapy for menopausal symptoms currently in phase III trials. Additionally, Mithra is advancing several other products, such as Myring, a contraceptive vaginal ring, and Zoreline, a biodegradable implant for treating prostate and breast cancers. Established in 1999 and headquartered in Liège, Belgium, Mithra Pharmaceuticals operates in multiple regions, including Belgium, Europe, and beyond, and offers a comprehensive spectrum of services through its CDMO, catering to research, development, and specialist manufacturing needs.

Starry, Inc. is an innovative internet company based in Boston, Massachusetts, with an additional operation in New York City. Founded in 2014, the company specializes in developing user-friendly Wi-Fi products and high-speed internet services. Its flagship product, Starry Station, is the first ambient touchscreen Wi-Fi router, designed to provide users with enhanced visibility and control over their home networks. In addition to its hardware, Starry employs advanced technologies to deliver high-speed broadband using hybrid-fiber fixed wireless solutions, offering gigabit-capable internet without the constraints of bundles, data caps, or long-term contracts. The company is committed to prioritizing customer needs, ensuring privacy, and promoting affordable connectivity and digital equity within communities.

CompoSecure Inc. specializes in the design and manufacturing of premium financial cards, focusing on high-security requirements for both public and private sectors. The company leverages its innovative metal payment card technology alongside its Arculus security and authentication capabilities to provide a superior branded experience. CompoSecure's offerings include metal cards that enhance the user experience and the Arculus digital security platform, which ensures secure access and trustworthy transactions. By combining advanced design with robust security features, CompoSecure aims to meet the evolving needs of its clients in the financial market.

Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.

BigBear.ai is a technology-focused company that specializes in decision intelligence solutions tailored for the national defense and intelligence sectors. The company offers a wide range of high-end capabilities, including artificial intelligence, machine learning, data science, and advanced analytics. Its services encompass offensive and defensive cybersecurity, data management, cloud solutions, digital engineering, and systems integration. BigBear.ai operates through two main segments: Cyber & Engineering and Analytics, serving various markets such as supply chains, logistics, autonomous systems, and cybersecurity. By leveraging its expertise in data and digital technologies, BigBear.ai aims to provide information superiority and robust decision support to its clients.

Lime is a transportation company that focuses on providing sustainable solutions for urban mobility by offering electric scooters and bike-sharing services. The company partners with cities to deploy a fleet of electric bikes and scooters equipped with GPS and self-activating locks, which allows users to access affordable and reliable transportation options. Lime aims to address the first- and last-mile transportation challenges, promoting environmentally friendly alternatives that help reduce carbon footprints. By encouraging a shift in transportation behavior, Lime seeks to empower future generations to contribute to a more sustainable planet.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Quotient Biodiagnostics specializes in the development and provision of high-quality immunohematology products for hospitals and blood banks in the United States. The company leverages over 30 years of expertise in research, development, and manufacturing through its wholly-owned subsidiary, Alba Bioscience. Quotient offers a range of transfusion diagnostics products that have been distributed globally, either directly or through partnerships with major transfusion companies. By focusing on the needs of healthcare institutions, Quotient aims to enhance the quality and reliability of blood transfusion practices.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

Amryt Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for patients with serious and life-threatening rare diseases. Founded in 2015 and based in London, the company offers several commercial products, including Myalept, which treats complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Amryt Pharma is also advancing its research pipeline, including FILSUVEZ, aimed at treating the skin manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. The company markets its products across the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Protalix Biotherapeutics is a biopharmaceutical company based in Karmiel, Israel, specializing in the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company is known for its product Elelyso, a plant-expressed recombinant glucocerebrosidase enzyme approved for treating Gaucher disease. Protalix is advancing a diverse pipeline that includes PRX-102, currently in phase III trials for Fabry disease, and OPRX-106, an orally delivered protein candidate for inflammatory bowel disease. Other products in development include PRX-110 for cystic fibrosis and PRX-115 for gout. Protalix has established partnerships with notable organizations, including Pfizer, which collaborates on the development and commercialization of Elelyso outside of Israel. Founded in 1993, Protalix is focused on addressing significant medical needs through its innovative biopharmaceutical solutions.

Inseego Corporation, established in 1996 and headquartered in San Diego, California, specializes in designing and developing mobile, IoT, and cloud solutions for diverse global clients, including large enterprises, service providers, and small to medium-sized businesses. The company offers a range of wireless hardware products, such as 4G and 5G fixed wireless routers, mobile hotspots, and IoT-specific devices, along with supporting software and cloud services for data analysis and remote hardware management. Inseego also provides software-as-a-service (SaaS) solutions, including fleet management, asset tracking, and usage-based insurance platforms, primarily under its Ctrack brand. Additionally, the company offers business connectivity solutions and device management services. Its primary revenue streams originate from the United States and Canada.

Emergent Payments, Inc. specializes in providing comprehensive payment solutions tailored for merchants in emerging markets across Latin America, Asia, India, and Eastern Europe. The company operates the Pay+ platform, which supports a variety of payment methods including international and local cards, bank transfers, digital wallets, and cash-based transactions. In addition to payment facilitation, Emergent Payments offers robust risk management, tax compliance solutions, and end-to-end technical support for its clients, which range from digital entertainment to educational publishing. Founded in 2007 and headquartered in Palo Alto, California, Emergent Payments has development centers in North Carolina and Shanghai, along with offices in several key global markets including India, China, and South Korea. The company rebranded from Live Gamer, Inc. in 2015 to concentrate on its payment technology and operations in high-growth international markets.

ACE*COMM Corporation was a provider of operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Their solutions were designed for wired, wireless, voice, data, multimedia, and Internet communication networks. Operating in various regions including the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific, ACE*COMM established strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. Founded in 1983 and headquartered in Gaithersburg, Maryland, the company focused on delivering essential tools for efficient network operations and management in the telecommunications industry.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

BravoSolution SpA specializes in supply management technology software and services aimed at enhancing procurement and sourcing processes. The company provides a range of solutions, including Spend Analysis to optimize savings and compliance, eSourcing for collaborative sourcing efforts, and supplier performance management tools. Its Contract Management service streamlines contract processes to ensure users realize savings from their negotiations. Notable products include BravoAlign, a cloud-based procurement alignment solution, and BravoAdvantage, a comprehensive platform that supports procurement initiatives from demand to contract. Additionally, BravoAdvantage Analytics offers data visualization tools, enabling procurement professionals to create intuitive reports and dashboards. BravoSolution also delivers collaboration services and government solutions related to spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates offices in multiple countries, including the United States, Brazil, and several European nations. As of late 2017, it functions as a subsidiary of JAGGAER, Inc.

Pharmacopeia, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutics for unmet medical needs. The company's internal program portfolio includes PS433540, a dual-acting angiotensin and endothelin receptor antagonist currently in phase II clinical development for cardiovascular and renal diseases, such as hypertension and diabetic nephropathy. Additionally, PS178990, a muscle selective SARM agonist, is in phase I clinical development. Pharmacopeia also has a preclinical product, PS031291, aimed at treating multiple myeloma and inflammatory diseases like rheumatoid arthritis, as well as JAK3 inhibitors targeting T-cell and cytokine mediated dermatologic and ocular conditions, including psoriasis and dry eye. The company has formed strategic alliances with several pharmaceutical firms, enhancing its research and development capabilities. Founded in 1993 and based in Cranbury, New Jersey, Pharmacopeia was previously known as Pharmacopeia Drug Discovery, Inc. and became a subsidiary of Ligand Pharmaceuticals Inc. in 2008.

Lexar is a prominent global brand specializing in memory and connectivity solutions, with a product portfolio that includes memory cards, USB flash drives, card readers, and solid-state drives. With over 20 years of experience, Lexar caters to various markets, including gaming, professional photography, and personal data management. The company ensures the reliability and quality of its products through rigorous testing at its Quality Labs, which feature over 1,100 digital devices for comprehensive evaluation. Lexar’s products are widely available through major retail and online stores, making it accessible to a broad audience seeking dependable memory solutions.

Strategic Data Corp. is an interactive technology company focused on optimizing the delivery of online advertising. Founded in 1999, SDC has specialized in developing display ad serving and yield-optimization technology that significantly increases the revenue for its clients. Currently, it operates as a subsidiary of Fox Interactive Media.